Phase IV Trial Opens: AI-Enhanced Bolus Priming in Automated Insulin Delivery for Type 1 Diabetes — AIDANET Study

References

1. 1.Battelino
2. 2.T.
3. 3.Danne
4. 4.T.
5. 5.Bergenstal
6. 6.R. M.
7. 7.Amiel
8. 8.S. A.
9. 9.Beck
10. 10.R.
11. 11.Biester
12. 12.T.
13. 13.... & Heller
14. 14.S. (2019). Clinical targets for continuous glucose monitoring data interpretation: Recommendations from the international consensus on time in range. Diabetes Care
15. 15.42(8)
16. 16.1593-1603. https://doi.org/10.2337/dci19-0028
17. 17.Beck
18. 18.R. W.
19. 19.Bergenstal
20. 20.R. M.
21. 21.Cheng
22. 22.P.
23. 23.Kollman
24. 24.C.
25. 25.Carlson
26. 26.A. L.
27. 27.Johnson
28. 28.M. L.
29. 29.& Rodbard
30. 30.D. (2019). The relationships between time in range
31. 31.hyperglycemia metrics
32. 32.and HbA1c. Diabetes Technology & Therapeutics
33. 33.21(2)
34. 34.81-85. https://doi.org/10.1089/dia.2018.0310
35. 35.Boughton
36. 36.C. K.
37. 37.& Hovorka
38. 38.R. (2023). Advances in artificial pancreas systems. Science Translational Medicine
39. 39.15(679)
40. 40.eabq6723. https://doi.org/10.1126/scitranslmed.abq6723
41. 41.Brown
42. 42.S. (2024). Effectiveness of Artificial-Intelligence (AI) Bolus Priming Added to an Existing Fully Automated Control Algorithm (AIDANET) [Clinical trial registration NCT07517770